Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue

Molecular Carcinogenesis

Volumn 45, Issue 8, 2006, Pages 613-626

  Brown, Lewis M ^a   Helmke, Steve M ^b   Hunsucker, Stephen W ^a   Netea Maier, Romana T ^d   Chiang, Simon A ^a   Heinz, David E ^b   Shroyer, Kenneth R ^b,c   Duncan, Mark W ^a,b,c   Haugen, Bryan R ^b,c  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DIGE; Molecular markers; Proteomics; Thyroid cancer

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; PHOSPHOPROTEIN PHOSPHATASE 2A;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ARTICLE; DNA FINGERPRINTING; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA;

AMINO ACID SEQUENCE; CARCINOMA, PAPILLARY; CELL CYCLE PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROGNOSIS; PROTEOMICS; S100 PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747011106     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20193     Document Type: Article

References (61)

1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-559.
2. Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf) 2002;56:281-290.
3. Ringel MD. Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. Rev Endocr Metab Disord 2000;1:173-181.
4. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
5. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16:34-41.
6. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
7. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-511.
8. Fagin JA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia. J Clin Endocrinol Metab 1992;75:1398-1400.
9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
10. Fagin JA. Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004;89:4264-4266.
11. Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 2004;64:2898-2903.
12. Finley DJ, Arora N, Zhu BX, Gallagher L, Fahey TJ. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-3223.
13. Cerutti JM, Delcelo R, Amadei MJ, et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004;113:1234-1242.
14. WesselD, Flugge UI. A method for the quantitative recovery of protein in dilute-solution in the presence of detergents and lipids. Anal Biochem 1984;138:141-143.
15. Bradford MM. Rapid and sensitive method for guantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 1976;72:248-254.
16. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997;18:2071-2077.
17. Knowles MR, Cervino S, Skynner HA, et al. Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis. Proteomics 2003;3:1162-1171.
18. Nicolls MR, D'Antonio JM, Hutton JC, Gill RG, Czwornog IL, Duncan MW. Proteomics as a tool for discovery: Proteins implicated in Alzheimer's disease are highly expressed in normal pancreatic islets. J Proteome Res 2003;2:199-205.
19. Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A. The need for guidelines in publication of peptide and protein identification data-Working group on publication guidelines for peptide and protein identification data. Mol Cell Proteomics 2004;3:531-533.
20. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001;98:15044-15049.
21. Fluge O, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 2002;21:5056-5068.
22. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are upregulated in papillary thyroid carcinoma: A cDNA and tissue microarray study. Clin Cancer Res 2003;9:68-75.
23. Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 2004;22:3531-3539.
24. Finley DJ, Zhu BX, Barden CB, Fahey TJ. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 2004;240:425-436.
25. Pauws E, Veenboer GJM, Smit JWA, de Vijlder JJM, Morreau H, Ris-Stalpers C. Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles. FASEB J 2004;18:560-561.
26. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N. High-throughput differential screening of mRNAs by serial analysis of gene expression: Decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer 2004;90:1600-1605.
27. Yano Y, Uematsu N, Yashiro T, et al. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 2004;10:2035-2043.
28. Chevillard S, Ugolin N, Vielh P, et al. Gene expression profiling of differentiated thyroid neoplasms: Diagnostic and clinical implications. Clin Cancer Res 2004;10:6586-6597.
29. Lin JD, Chan EC, Weng HF, Sheu CA. Two-dimensional electrophoretic analysis of membranous protein from human thyroid tissues and cancer cell lines. Electrophoresis 1998;19:3213-3216.
30. Srisomsap C, Subhasitanont P, Otto A, et al. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2002;2:706-712.
31. Lin JD, Huang CC, Weng HF, Chen SC, Jeng LB. Comparison of membrane proteins from benign and malignant human thyroid tissues by two-dimensional polyacrylamide gel electrophoresis. J Chromatogr B Biomed Appl 1995;667:153-160.
32. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 2004;3:960-969.
33. Seike M, Kondo T, Fujii K, et al. Proteomic signature of human cancer cells. Proteomics 2004;4:2776-2788.
34. Friedman DB, Hill S, Keller JW, et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004;4:793-811.
35. Daikoku T, Tranguch S, Friedman DB, Das SK, Smith DF, Dey SK. Proteomic analysis identifies immunophilin FKBP52 as a downstream target of Hoxa10 in the periimplantation mouse uterus. Mol Endocrinol 2004.
36. Rosai J. Immunohistochemical markers of thyroid tumors: Significance and diagnostic: applications. Tumori 2003;89:517-519.
37. Anderson CE, McLaren KM. Best practice in thyroid pathology. J Clin Pathol 2003;56:401-405.
38. Shuja S, Murnane MJ. Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. Int J Cancer 1996;66:420-426.
39. Marenholz I, Heimann CW, Fritz G. S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004;322:1111-1122.
40. McLaren KM, Cossar DW. The immunohistochemical localization of S100 in the diagnosis of papillary carcinoma of the thyroid. Hum Pathol 1996;27:633-636.
41. Kilicarslan B, Pesterelli EH, Oren N, Sargin FC, Karpuzoglu G. Epithelial membrane antigen and S-100 protein expression in benign and malignant papillary thyroid neoplasms. Adv Clin Path 2000;4:155-158.
42. Mitselou A, Vougiouklakis TG, Peschos D, Dallas P, Boumba VA, Agnantis NJ. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions. Anticancer Res 2002;22:1777-1780.
43. Ilg EC, Schaler BW, Heizmann CW. Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer 1996;68:325-332.
44. Brown LM, Helmke S, Baltz JL, Hunsucker SW, Haugen BR, Duncan MW. Difference gel electrophoresis and MALDI-ToF mass spectrometric analysis of papillary carcinoma of the thyroid. Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics, May 23-27, 2004. Nashville, Tennessee. 2004. American Society for Mass Spectrometry.
45. Ito Y, Yoshida H, Tomoda C, et al. Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology 2005;46:569-575.
46. Dunn AD, Crutchfield HE, Dunn JT. Thyroglobulin processing by thyroidal proteases. Major sites of cleavage by cathepsins B, D, and L. J Biol Chem 1991;266:20198-20204.
47. Rempel SA, Rosenblum ML, Mikkelsen T, et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 1994;54:6027-6031.
48. Gondi CS, Lakka SS, Yanamandra N, et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004;64:4069-4077.
49. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. Going malignant: The hypoxia-cancer connection in the prostate. Bioessays 2002;24:749-757.
50. Shinohara Y, Ishida T, Hino M, Yamazaki N, Baba Y, Terada H. Characterization of porin isoforms expressed in tumor cells. Eur J Biochem 2000;267:6067-6073.
51. Heddi A, FaureVigny H, Wallace DC, Stepien G. Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Biochimica Et Biophysica Acta-Mol Basis Disease 1996;1316:203-209.
52. Wang FL, Wang YB, Wong WK, et al. Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res 1996;56:3634-3637.
53. Simon HG, Risse B, Jost M, Oppenheimer S, Kari C, Rodeck U. Identification of differentially expressed messenger RNAs in human melanocytes and melanoma cells. Cancer Res 1996;56:3112-3117.
54. Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 2001;86:4920-4925.
55. Baris O, Savagner F, Nasser V, et al. Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 2004;89:994-1005.
56. Haugen DRF, Fluge O, Reigstad LJ, Varhaug JE, Lillehaug JR. Increased expression of genes encoding mitochondrial proteins in papillary thyroid carcinomas. Thyroid 2003;13:613-620.
57. Tonietti G, Baschieri L, Salabe G. Papillary and microfibrilllar carcinoma of human thyroid. An ultrastuctural study. Arch Path 1967;84:601-614.
58. Albores-Saavedra J, Altamirano-Dimas M, Alcorta-Anguizola B, Smith M. Fine structure of human papillary thyroid carcinoma. Cancer 1971;28:763-774.
59. Stefaneanu L, Tasca C. An electron-microscopic study of human thyroid cancer. Endocrinologie 1979;17:233-239.
60. Valenta LJ, Michel-Bechet M. Ultrastructure and biochemistry of thyroid carcinoma. Cancer 1977;40:284-300.
61. Hammack BN, Fung KYC, Hunsucker SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004;10:245-260.